Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. reports news on its dermatology therapeutics business, including commercialization of YCANTH (VP-102) for molluscum contagiosum and development of cantharidin-based therapy for common warts. Company updates also cover financial results, corporate presentations, commercial leadership and international commercialization activity.
Verrica’s pipeline news centers on VP-315 (ruxotemitide), an oncolytic peptide licensed for dermatologic oncology indications. Recurring disclosures include clinical data presentations in basal cell carcinoma, development plans for non-melanoma skin cancers and collaboration activity tied to YCANTH and its dermatology portfolio.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced the initiation of Part 2 of its Phase 2 clinical trial for VP-315, aimed at treating basal cell carcinoma (BCC). The first patient has been dosed, following positive outcomes from Part 1, which showed a favorable safety profile and clinical activity in higher dose ranges. This trial part seeks to optimize dosing regimens before advancing to Part 3, projected to commence in the first half of 2024. VP-315, an innovative oncolytic peptide therapy, offers a non-surgical treatment for the approximately 3-4 million BCC cases diagnosed annually in the U.S. The trial will enroll about 66 adult subjects. This advancement aligns with Verrica's focus on unmet medical needs in dermatology.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced that its President and CEO, Ted White, will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023. The presentation, scheduled for 2:15 – 2:55 PM ET, will allow attendees to hear about Verrica's advancements in dermatology therapeutics, especially their late-stage product candidate, VP-102, aimed at treating molluscum, common warts, and external genital warts. Additionally, Verrica is developing VP-103 for plantar warts and has entered a global licensing agreement with Lytix Biopharma AS for the commercialization of VP-315. A live webcast of the event will be available on Verrica's website and will remain accessible for 30 days after the conference.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced a PDUFA goal date of July 23, 2023, for its NDA of VP-102, aimed at treating molluscum contagiosum, potentially benefiting six million U.S. patients. The company raised $32.5 million in a secondary offering, providing capital to fund operations through Q1 2024. VP-315, an oncolytic peptide immunotherapy for basal cell carcinoma, is progressing to its Phase 2 trial's second part in Q2 2023. Financially, Verrica reported a net loss of $24.5 million for 2022, with reduced R&D costs and an increase in collaboration revenue to $9 million. Cash reserves stood at $34.3 million at year-end 2022.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announces that its President and CEO, Ted White, will participate in a fireside chat at The Cowen 43rd Annual Health Care Conference in Boston, MA, on March 6, 2023, from 2:50 PM to 3:20 PM ET. A live webcast of the event will be accessible via the provided link and on Verrica's website. The company is focused on dermatology therapeutics, with key products like VP-102 and VP-103 aimed at treating significant skin conditions, including warts. Verrica has also secured a worldwide license with Lytix Biopharma AS for developing VP-LTX-315 for dermatologic oncology. More details are available on their official website.